Ongoing efforts in bladder cancer have yielded significant improvements in the care of patients, especially in the metastatic setting, through FGFR2/3 targeting, as well as with immunotherapy options with PD-L1 inhibitors. This evidence concerns the gene FGFR2 and urinary bladder carcinoma.